ArticleJournal of cancer research and clinical oncology2025
Characteristics and antimicrobial therapy of bloodstream infections in tumour patients with special reference to antibiotic stewardship.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical characteristics and risk factor analysis of multidrug-resistant bacterial bloodstream infections in adult acute leukemia patients.Frontiers in microbiology · 2026Article
- Gram-negative bacterial bloodstream infections in cancer patients: a study of epidemiological trends and antibiotic susceptibility.Tropical medicine and health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bloodstream infections (BSI) are among the most frequent infections in tumour patients. We analysed 123 tumour patients (105 retrospective, 18 prospective) with BSI. The most common underlying tumour diseases were acute leukaemia/myelodysplastic syndrome (40%), followed by lymphomas (25%) and multiple myeloma (20%). BSI were more frequently caused by Gram-negative than Gram-positive bacteria (53% vs. 40%), including Escherichia coli (33%), coagulase-negative Staphylococcus spp. (14%), and Pseudomonas aeruginosa (10%). The median time to fever resolution was 3 days (range 1-30 days). Neither pathogen type, initial antibiotic treatment, nor key patient characteristics significantly affected fever resolution time. Non-susceptibility of the pathogen to empirical antibiotic treatment was linked to prolonged fever resolution (HR 0.53, 95%-CI 0.28-1.0, p = 0.04). The severity of neutropenia on admission had a significant impact on 60-day survival (HR 2.95, 95%-CI 1.10-7.93, p = 0.03). In contrast, such an effect on survival was not observed by the non-susceptibility of the pathogen to primary empirical antibiotic treatment (HR 2.12, 95%-CI 0.71-6.30, p = 0.18). Non-adherence or questionable adherence to antibiotic stewardship (ABS) recommendations (n = 42, 34%) correlated with delayed fever resolution (median 3 days vs. 4 days; p = 0.04) and was more frequent in retrospectively than in prospectively recorded patients (38% vs. 11%, p = 0.03). Gram-negative bacteria still predominate as BSI agents in tumour patients. Prospective evaluation of anti-infective management may enhance adherence to ABS recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.